ASCO 2024 | BIG BANG: binimetinib, encorafenib, and cetuximab in BRAF non-V600E mutated mCRC

Daisuke Kotani, MD, National Cancer Center Hospital East, Kashiwa, Japan, discusses findings from the Phase II BIG BANG trial (UMIN000031857) of binimetinib, encorafenib, and cetuximab in patients with BRAF non-V600E mutated metastatic colorectal cancer (mCRC). The combination therapy had modest efficacy and the safety profile was manageable, with ongoing circulating tumor DNA analyses underway to further evaluate treatment impact. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.